RESVERLOGIX CORP (RVX.CA) Stock Price, Forecast & Analysis
TSX:RVX • CA76128M1086
RVX.CA Key Statistics, Chart & Performance
The current stock price of RVX.CA is 0.095 CAD. In the past year, price increased by 90%.
RVX.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to RVX.CA. When comparing the yearly performance of all stocks, RVX.CA is one of the better performing stocks in the market, outperforming 76.27% of all stocks.
RVX.CA Financial Highlights
Over the last trailing twelve months RVX.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 41.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -90.47% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RVX.CA Forecast & Estimates
RVX.CA Ownership
RVX.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 560.189M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 378.8M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 141.303M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 63.392M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.11 | 44.744M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.57 | 31.273M | ||
| HEM | HEMOSTEMIX INC | N/A | 15.079M | ||
| MPH | MEDICURE INC | N/A | 11.693M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 10.49M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About RVX.CA
Company Profile
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 18 full-time employees. The company went IPO on 2001-10-12. The firm focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The firm's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. The company partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Company Info
RESVERLOGIX CORP
300-4820 Richard Rd SW
Calgary ALBERTA T3E 6L1 CA
CEO: Donald J. McCaffrey
Employees: 18
Phone: 14032549252
RESVERLOGIX CORP / RVX.CA FAQ
What does RESVERLOGIX CORP do?
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 18 full-time employees. The company went IPO on 2001-10-12. The firm focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The firm's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. The company partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Can you provide the latest stock price for RESVERLOGIX CORP?
The current stock price of RVX.CA is 0.095 CAD. The price decreased by -13.64% in the last trading session.
What is the dividend status of RESVERLOGIX CORP?
RVX.CA does not pay a dividend.
How is the ChartMill rating for RESVERLOGIX CORP?
RVX.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is RESVERLOGIX CORP (RVX.CA) stock traded?
RVX.CA stock is listed on the Toronto Stock Exchange exchange.
Can you provide the market cap for RESVERLOGIX CORP?
RESVERLOGIX CORP (RVX.CA) has a market capitalization of 27.30M CAD. This makes RVX.CA a Nano Cap stock.